Pages
Products

BACE1


Official Full Name
beta-secretase 1
Organism
Homo sapiens
Gene ID
23621
Background
This gene encodes a member of the peptidase A1 family of aspartic proteases. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature protease. This transmembrane protease catalyzes the first step in the formation of amyloid beta peptide from amyloid precursor protein. Amyloid beta peptides are the main constituent of amyloid beta plaques, which accumulate in the brains of human Alzheimer's disease patients. [provided by RefSeq, Nov 2015]
Synonyms
ASP2; BACE; HSPC104
Bio Chemical Class
Peptidase
Protein Sequence
MAQALPWLLLWMGAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDESTLMTIAYVMAAICALFMLPLCLMVCQWRCLRCLRQQHDDFADDISLLK
Open
Disease
Alzheimer disease
Approved Drug
0
Clinical Trial Drug
3 +
Discontinued Drug
0

Cat.No. Product Name Price
SHH244568 shRNA set against Mouse BACE1 (NM_011792.5) Inquiry
SHH244570 shRNA set against Rat BACE1 (NM_019204.1) Inquiry
SHG066877 shRNA set against Rat Bace1(NM_019204.1) Inquiry
SHH244562 shRNA set against Human BACE1 (NM_138973.3) Inquiry
SHW017612 shRNA set against Danio rerio BACE1 (NM_205704) Inquiry
Cat.No. Product Name Price
CDCB157344 Mouse BACE1 ORF clone (NM_011792.4) Inquiry
CDFR011501 Rat Bace1 cDNA Clone(NM_019204.1) Inquiry
MiUTR1R-00504 BACE1 miRNA 3'UTR clone Inquiry
MiUTR3H-06677 BACE1 miRNA 3'UTR clone Inquiry
CDCB179087 Danio rerio BACE1 ORF Clone (NM_205704) Inquiry
CDCB191655 Rabbit BACE1 ORF clone (XM_002708373.2) Inquiry
CDCG001458 Mouse BACE1 ORF clone(NM_011792.5) Inquiry
CDCR032928 Mouse Bace1 ORF clone (NM_001145947.1) Inquiry
CDCR032934 Human BACE1 ORF clone (NM_001207049.1) Inquiry
CDCR032936 Human BACE1 ORF clone (NM_001207048.1) Inquiry
CDCR378364 Rat Bace1 ORF Clone(NM_019204.1) Inquiry
CDCS409707 Human BACE1 ORF Clone (BC065492) Inquiry

Detailed Information

The production of 40 or 42 amino acids long amyloid-β peptide accumulated in the brain is the central pathological feature of Alzheimer's disease and largely consists of amyloid-β peptides. Amyloid-β is formed through sequential proteolytic processing of the amyloid precursor protein (APP), catalyzed by the β- and γ-secretases. The aspartyl protease β-site APP cleaving enzyme 1 (BACE1) cleaves APP predominantly at a unique site, whereas the c-secretase complex cleaves the resulting carboxy-terminal fragment at several sites, with preference for positions 40 and 42, leading to formation of amyloid β1-40 (Aβ1-40) and Aβ1-42 peptides.

Extracellular cleavage of APP by BACE1 produces soluble extracellular fragments and a cell membrane-bound fragment referred to as C99. Cleavage of C99 within its transmembrane domain by γ-secretase releases the intracellular domain of APP and produces amyloid-β. Since γ-secretase cleaves APP closer to the cell membrane than BACE1 does, it removes a fragment of the amyloid-β peptide. Initial cleavage of APP by α-secretase instead of BACE1 prevents the final production of amyloid-β. Unlike APP and the presenilin proteins important in γ-secretase, no known mutations in the gene encoding BACE1 lead to early-onset, familial Alzheimer's disease, which is a rare form of the disorder. Nevertheless, it has been shown that this level of enzyme is elevated in the more common late-onset sporadic Alzheimer's disease. The physiological purpose of BACE cleavage of APP and other transmembrane proteins is unclear. BACE2 is a close homolog of BACE1 and there is no reported APP cleavage in vivo. However, single residue mutations in APP reduce the ability of BACE1 to cleave it to produce amyloid-beta and reduce the risk of Alzheimers and other cognitive declines. Thorlakur et al. has shown that a coding mutation (A673T) in the APP gene that protects against Alzheimer’s disease and cognitive decline in the elderly without Alzheimer’s disease. This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro. The A673T substitution is located at position 2 in the amyloid-β peptide.

Fig 1. Processing of the amyloid precursor protein.

Wanxia et al. has identificated reticulon family members as binding partners of BACE1. RTN3 and RTN4B are members of the reticulon family, all of which contain a highly conserved reticulon homology domain (RHD) of about 188 amino acids with two putative transmembrane regions separated by a 66-residue loop. They found that two membrane-associated proteins, RTN3 and RTN4B, are both present in BACE1 immunocomplexes. The reticulon family of cellular proteins interacts with BACE1 and decreases both BACE1 cleavage of APP and Aβ production. RTN3 is the principal BACE1-interacting protein in human brain. It seems conceivable that small changes in reticulon expression in human brain might potentially affect long-term Aβ production and that, in turn, this could either accelerate or decelerate the deposition of amyloid in brain. Overexpression of RTN3 can inhibit Aβ production, owing to the sequestering of BACE1 away from its cellular APP substrate. Reticulon proteins share a highly conserved membrane-associated RHD, but their N-terminal regions are divergent. All tested reticulon proteins bind to BACE1 and inhibit its activity, suggesting that reticulon proteins have shared functions in addition to the specific roles mediated by their distinct N-terminal domains. The physiological meaning of the binding of reticulon proteins to BACE1 remains to be discovered. It is also unclear whether or not BACE1 binds to reticulon proteins directly. It is possible that the binding of BACE1 to reticulon proteins is in an ‘on-and-off’ state in cells because the binding of endogenous proteins is clearly weak. Increasing the expression of either RTN3 or BACE1 increased this binding and the increase in binding clearly blocked the interaction of BACE1 with its cellular APP substrate and reduced the catalytic action of BACE1.

References:

  1. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jönsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K (Aug 2012). "A mutation in APP protects against Alzheimer's disease and age-related cognitive decline". Nature. 488 (7409): 96–9.
  2. Russo I, Babbitt S, Muralidharan V, Butler T, Oksman A, Goldberg DE. Plasmepsin V licenses. Plasmodium proteins for export into the host erythrocyte. Nature. 2010;463(7281):632-636.
  3. He W1, Lu Y, Qahwash I, Hu XY, Chang A, Yan R. Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation. Nat Med. 2004 Sep;10(9):959-65. Epub 2004 Aug 1.
  4. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C (Oct 2006). "Control of peripheral nerve myelination by the beta-secretase BACE1". Science. 314 (5799): 664–6.
Quick Inquiry